197 related articles for article (PubMed ID: 35614862)
1. [Real-world efficacy of switching to bictegravir/ emtricitabine/tenofovir alafenamide in pretreated patients with triple therapy containing rilpivirine].
de Gea Grela A; Martín Carbonero L; Micán R; Bernardino JI; Ramos L; Valencia ME
Rev Esp Quimioter; 2022 Aug; 35(4):378-381. PubMed ID: 35614862
[TBL] [Abstract][Full Text] [Related]
2. Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.
Orkin C; Antinori A; Rockstroh JK; Moreno-Guillén S; Martorell CT; Molina JM; Lazzarin A; Maggiolo F; Yazdanpanah Y; Andreatta K; Huang H; Hindman JT; Martin H; Pozniak A
AIDS; 2024 Jun; 38(7):983-991. PubMed ID: 38349226
[TBL] [Abstract][Full Text] [Related]
3. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts.
Esser S; Brunetta J; Inciarte A; Levy I; D'Arminio Monforte A; Lambert JS; van Welzen B; Teruya K; Boffito M; Liu CE; Altuntas Aydın O; Thorpe D; Heinzkill M; Marongiu A; Cassidy T; Haubrich R; D'Amato L; Robineau O
HIV Med; 2024 Apr; 25(4):440-453. PubMed ID: 38148567
[TBL] [Abstract][Full Text] [Related]
4. Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
Orkin C; Ajana F; Kityo C; Koenig E; Natukunda E; Gandhi-Patel B; Wang H; Liu Y; Wei X; White K; Makadzange T; Pikora C; McNicholl I; Collins SE; Brainard D; Chuck SK
J Acquir Immune Defic Syndr; 2021 Dec; 88(4):393-398. PubMed ID: 34506342
[TBL] [Abstract][Full Text] [Related]
5. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
Hagins D; Kumar P; Saag M; Wurapa AK; Brar I; Berger D; Osiyemi O; Hileman CO; Ramgopal MN; McDonald C; Blair C; Andreatta K; Collins SE; Brainard DM; Martin H;
J Acquir Immune Defic Syndr; 2021 Sep; 88(1):86-95. PubMed ID: 34397746
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.
Rodriguez CA; Natukunda E; Strehlau R; Venter EL; Rungmaitree S; Cunningham CK; Lalloo U; Kosalaraksa P; HellstrÖm E; Liberty A; McGrath EJ; Kaur M; Leisegang R; Hindman JT; Vieira VA; Kersey K; Cotton MF; Rakhmanina N; Gaur AH
Lancet HIV; 2024 May; 11(5):e300-e308. PubMed ID: 38621393
[TBL] [Abstract][Full Text] [Related]
7. Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection.
Mu Y; Pham M; Podany AT; Cory TJ
Expert Opin Pharmacother; 2020 Mar; 21(4):389-397. PubMed ID: 31957507
[No Abstract] [Full Text] [Related]
8. Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48-96 weeks of RETROBIC Study.
Troya J; Pousada G; Micán R; Galera C; Sanz J; de Los Santos I; Dueñas C; Cabello N; Martín C; Galindo MJ; Garcinuño MÁ; Pedrero-Tomé R; Buzón L
J Antimicrob Chemother; 2024 Mar; 79(3):595-607. PubMed ID: 38267266
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate for adult patients with human immunodeficiency virus-1 in China: a retrospective real-world cohort study.
Gan L; Xie X; Fu Y; Song Y; Song C; Ren T; Long H
Expert Rev Anti Infect Ther; 2024 Apr; 22(4):211-217. PubMed ID: 38058002
[TBL] [Abstract][Full Text] [Related]
10. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV from the Canadian cohort of the observational BICSTaR study.
Wong A; Brunetta J; De Wet J; Logue K; Loemba H; Saifi T; Mumm D; Marongiu A; Harrison R; Thorpe D; Trottier B
Medicine (Baltimore); 2024 Apr; 103(16):e37785. PubMed ID: 38640301
[TBL] [Abstract][Full Text] [Related]
11. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
12. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Wohl DA; Yazdanpanah Y; Baumgarten A; Clarke A; Thompson MA; Brinson C; Hagins D; Ramgopal MN; Antinori A; Wei X; Acosta R; Collins SE; Brainard D; Martin H
Lancet HIV; 2019 Jun; 6(6):e355-e363. PubMed ID: 31068270
[TBL] [Abstract][Full Text] [Related]
13. Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.
Hoffmann C; Schewe K; Fenske S; Buhk T; Sabranski M; Adam A; Hansen S; Stellbrink HJ
Antivir Ther; 2020; 25(2):83-90. PubMed ID: 32235038
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN; Castagna A; Cazanave C; Diaz-Brito V; Dretler R; Oka S; Osiyemi O; Walmsley S; Sims J; Di Perri G; Sutton K; Sutherland-Phillips D; Berni A; Latham CL; Zhang F; D'Amico R; Pascual Bernáldez M; Van Solingen-Ristea R; Van Eygen V; Patel P; Chounta V; Spreen WR; Garges HP; Smith K; van Wyk J
Lancet HIV; 2023 Sep; 10(9):e566-e577. PubMed ID: 37567205
[TBL] [Abstract][Full Text] [Related]
15. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
[TBL] [Abstract][Full Text] [Related]
16. High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
Sax PE; Andreatta K; Molina JM; Daar ES; Hagins D; Acosta R; D'Antoni ML; Chang S; Martin R; Liu H; Blair C; McNicholl I; Gallant J; Collins SE; Martin H; White KL
AIDS; 2022 Sep; 36(11):1511-1520. PubMed ID: 35466963
[TBL] [Abstract][Full Text] [Related]
17. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.
Ogbuagu O
Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1113-1126. PubMed ID: 27797606
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A; Tavelli A; Di Biagio A; Sarmati L; Marchetti GC; Bai F; Cingolani A; Quiros Roldan E; Mussini C; Lichtner M; Vergori A; Piconi S; Orofino G; Fusco FM; Bandera A; Nozza S; Castagna A; Antinori A;
J Antimicrob Chemother; 2024 Jun; 79(6):1279-1288. PubMed ID: 38581349
[TBL] [Abstract][Full Text] [Related]
19. Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.
Armenia D; Forbici F; Bertoli A; Berno G; Malagnino V; Gagliardini R; Borghi V; Gennari W; Cicalini S; Buonomini A; Teti E; Lanini S; Latini A; Sarmati L; Mussini C; Andreoni M; Antinori A; Perno CF; Ceccherini-Silberstein F; Santoro MM
J Glob Antimicrob Resist; 2022 Sep; 30():326-334. PubMed ID: 35793776
[TBL] [Abstract][Full Text] [Related]
20. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C; DeJesus E; Sax PE; Arribas JR; Gupta SK; Martorell C; Stephens JL; Stellbrink HJ; Wohl D; Maggiolo F; Thompson MA; Podzamczer D; Hagins D; Flamm JA; Brinson C; Clarke A; Huang H; Acosta R; Brainard DM; Collins SE; Martin H; ;
Lancet HIV; 2020 Jun; 7(6):e389-e400. PubMed ID: 32504574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]